Liang Yin, She Pengxiang, Wang Xiwei, Demarest Keith
Endocrine Therapeutic and Metabolic Disorders, Johnson and Johnson Pharmaceutical Research and Development, L.L.C., Spring House, PA, USA.
Metabolism. 2006 Oct;55(10):1411-9. doi: 10.1016/j.metabol.2006.06.013.
Topiramate (TPM) is a novel neurotherapeutic agent approved for the treatment of epilepsy and for migraine prophylaxis. It has been observed that in obese-associated, type 2 diabetic rodent models, TPM treatment reduced the body weight gain, improved insulin sensitivity, and enhanced glucose-regulated insulin release. A long-term treatment with TPM thus ameliorated obesity and diabetic syndromes in female Zucker diabetic fatty rats and db/db mice. The molecular mechanisms of TPM antiobesity and antidiabetic effects remain unknown. We have applied DNA microarray technology to explore genes that might be involved in the mechanisms by which TPM improves insulin sensitivity and blood glucose handling, as well as body weight control. In female Zucker diabetic fatty rats, 7-day TPM treatment significantly reduced the plasma levels of glucose and triglyceride in a dose-dependent manner. The DNA microarray data revealed that TPM treatment altered messenger RNA profiles in liver, hypothalamus, white adipose tissue, and skeletal muscle. The most marked effect of TPM on gene expression occurred in liver with those genes related with metabolic enzymes and signaling regulatory proteins involved in energy metabolism. TPM treatment decreased messenger RNA amounts for sterol regulatory element binding protein-1c, stearoyl-coenzyme A (CoA) desaturase-1, choline kinase, and fatty acid CoA ligase, long chain 4. TPM also up-regulated 3 cholesterol synthesis genes. In addition, the short-term effect of TPM on gene expression was examined at 16 hours after a single administration. TPM markedly reduced hepatic expression of genes related with fatty acid synthesis, eg, stearoyl-CoA desaturase and acetyl-CoA carboxylase. TPM also changed genes related with fatty acid beta-oxidation, increased 3-2-trans-enoyl-CoA isomerase and mitochondrial acyl-CoA thioesterase, and decreased fatty acid CoA ligase (long chain 2 and long chain 5). These gene expression changes were independent of food intake as shown by pair feeding. Our results suggest that TPM regulates hepatic expression of genes involved in lipid metabolism, which could be part of the mechanisms by which TPM reduces plasma triglyceride levels in obese diabetic rodents.
托吡酯(TPM)是一种新型神经治疗药物,已被批准用于治疗癫痫和预防偏头痛。据观察,在肥胖相关的2型糖尿病啮齿动物模型中,TPM治疗可减少体重增加、改善胰岛素敏感性并增强葡萄糖调节的胰岛素释放。因此,长期使用TPM可改善雌性Zucker糖尿病脂肪大鼠和db/db小鼠的肥胖和糖尿病综合征。TPM抗肥胖和抗糖尿病作用的分子机制尚不清楚。我们应用DNA微阵列技术来探索可能参与TPM改善胰岛素敏感性、血糖处理以及体重控制机制的基因。在雌性Zucker糖尿病脂肪大鼠中,7天的TPM治疗以剂量依赖的方式显著降低了血浆葡萄糖和甘油三酯水平。DNA微阵列数据显示,TPM治疗改变了肝脏、下丘脑、白色脂肪组织和骨骼肌中的信使核糖核酸(mRNA)谱。TPM对基因表达的最显著影响发生在肝脏,涉及与能量代谢相关的代谢酶和信号调节蛋白的那些基因。TPM治疗降低了固醇调节元件结合蛋白-1c、硬脂酰辅酶A(CoA)去饱和酶-1、胆碱激酶和脂肪酸CoA连接酶(长链4)的信使核糖核酸量。TPM还上调了3个胆固醇合成基因。此外,在单次给药后16小时检查了TPM对基因表达的短期影响。TPM显著降低了与脂肪酸合成相关的基因的肝脏表达,例如硬脂酰-CoA去饱和酶和乙酰-CoA羧化酶。TPM还改变了与脂肪酸β-氧化相关的基因,增加了3-2-反式烯酰-CoA异构酶和线粒体酰基-CoA硫酯酶,并降低了脂肪酸CoA连接酶(长链2和长链5)。如配对喂养所示,这些基因表达变化与食物摄入量无关。我们的结果表明,TPM调节参与脂质代谢的基因的肝脏表达,这可能是TPM降低肥胖糖尿病啮齿动物血浆甘油三酯水平机制的一部分。